Pharmaceutical Analytical Testing Outsourcing Market Analysis By Services (Bioanalytical Testing, Method Development and Validation, Stability Testing), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025
出 版 商：Grand View Research
出版日期：2017/01/18
頁 數：100頁
文件格式：PDF
價 格：
USD 4,950 (Single-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
The global pharmaceutical analytical testing outsourcing market is expected to reach USD 9.6 billion by 2025, according to a new report by Grand View Research, Inc. The performance of market players in pharmaceutical analytical testing domain is highly influenced by the level of demand from end-user side. Due to intense market efforts, increasing awareness level, improving accessibility, and government initiatives, consumers, these days, are more concerned about self-care, resulting in higher consumption of pharmaceutical products.
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand. As a result, companies have to realign their manufacturing capabilities to meet the increasing demand.
A major price difference between conducting analytical tests in-house and outsourcing has been observed. Companies may lack the required set-up and expertise to perform every possible test in-house. In addition, there are serval no routine activities that are needed to be performed only once. These include registration stability storage & testing, process & facility validation work, cleaning validations, analytical testing using expensive equipment & method development. For such tests, the best option is to outsource it to a specialty firm that has expertise and experience in this vertical. Outsourcing benefits companies with various aspects such as personnel management and reduction of equipment, validation & maintenance cost.
Further key findings from the study suggest:
The other methods of validation services include cleaning validation services, analytical standard characterization, and peak identification. These services are anticipated to witness growth over the forecast period.
Clinical bioanalytical testing market is likely to witness growth rate of over 8.0% during the forecast period owing to the increasing number of clinical trials coupled with a strengthened regulatory framework to perform drug discovery and development process at par with excellence.
North America is expected to dominate the market at a global level owing to the better quality and propelling research activities being conducted within the region.
Some of the key players in this market include SGS SA; Toxikon, Inc.; Eurofins Scientific; Pharmaceutical Product Development, LLC; Intertek Group plc; Pace Analytical Services, LLC; Exova Group plc; Boston Analytical; Charles River Laboratories International Inc.; and West Pharmaceutical Services, Inc. Regional & service portfolio expansions and merger & acquisitions are key strategic undertakings of these players.
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand. As a result, companies have to realign their manufacturing capabilities to meet the increasing demand.
A major price difference between conducting analytical tests in-house and outsourcing has been observed. Companies may lack the required set-up and expertise to perform every possible test in-house. In addition, there are serval no routine activities that are needed to be performed only once. These include registration stability storage & testing, process & facility validation work, cleaning validations, analytical testing using expensive equipment & method development. For such tests, the best option is to outsource it to a specialty firm that has expertise and experience in this vertical. Outsourcing benefits companies with various aspects such as personnel management and reduction of equipment, validation & maintenance cost.
Further key findings from the study suggest:
The other methods of validation services include cleaning validation services, analytical standard characterization, and peak identification. These services are anticipated to witness growth over the forecast period.
Clinical bioanalytical testing market is likely to witness growth rate of over 8.0% during the forecast period owing to the increasing number of clinical trials coupled with a strengthened regulatory framework to perform drug discovery and development process at par with excellence.
North America is expected to dominate the market at a global level owing to the better quality and propelling research activities being conducted within the region.
Some of the key players in this market include SGS SA; Toxikon, Inc.; Eurofins Scientific; Pharmaceutical Product Development, LLC; Intertek Group plc; Pace Analytical Services, LLC; Exova Group plc; Boston Analytical; Charles River Laboratories International Inc.; and West Pharmaceutical Services, Inc. Regional & service portfolio expansions and merger & acquisitions are key strategic undertakings of these players.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Pharmaceutical Analytical Testing Outsourcing Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Penetration & Growth Prospect Mapping
3.4. SWOT Analysis, By Factor
3.4.1. Political
3.4.2. Economic
3.4.3. Technological
3.5. Industry Analysis - Porter’s
Chapter 4. Pharmaceutical Analytical Testing Outsourcing: Services Estimates & Trend Analysis
4.1. Pharmaceutical Analytical Testing Services Outsourcing Market Share, 2015 & 2025
4.2. Market Size, Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following services:
4.2.1. Bioanalytical Testing
4.2.1.1. Clinical
4.2.1.2. Non Clinical
4.2.2. Method Development & Validation
4.2.2.1. Extractable & Leachable
4.2.2.2. Impurity Method
4.2.2.3. Technical Consulting
4.2.2.4. Others
4.2.3. Stability Testing
4.2.3.1. Drug Substance
4.2.3.2. Stability indicating Method Validation
4.2.3.3. Accelerated Stability Testing
4.2.3.4. Photostability Testing
4.2.3.5. Others
4.2.4. Others
Chapter 5. Pharmaceutical Analytical Testing Outsourcing: Regional Estimates & Trend Analysis
5.1. Pharmaceutical Analytical Testing Services Outsourcing Movement Analysis & Market Share, 2015 & 2025
5.2. North America
5.2.1. U.S.
5.2.1.1. U.S. revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.2.2. Canada
5.2.2.1. Canada revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.3. Europe
5.3.1. UK
5.3.1.1. UK revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.3.2. Germany
5.3.2.1. Germany revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Japan
5.4.1.1. Japan revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.4.2. China
5.4.2.1. China revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.5. Latin America
5.5.1. Brazil
5.5.1.1. Brazil revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.5.2. Mexico
5.5.2.1. Mexico revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.6. MEA
5.6.1. South Africa
5.6.1.1. South Africa revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
Chapter 6. Competitive Landscape
6.1. Strategy Framework
6.2. Company Profiles
6.2.1. SGS SA
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Geographic Foothold
6.2.1.4. Product Benchmarking
6.2.1.5. Strategic Initiatives
6.2.1.6. SWOT Analysis
6.2.2. Toxikon, Inc
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Geographic Foothold
6.2.2.4. Product Benchmarking
6.2.2.5. Strategic Initiatives
6.2.2.6. SWOT Analysis
6.2.3. Eurofins Scientific
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Geographic Foothold
6.2.3.4. Product Benchmarking
6.2.3.5. Strategic Initiatives
6.2.3.6. SWOT Analysis
6.2.4. Pace Analytical Services LLC.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Geographic Foothold
6.2.4.4. Product Benchmarking
6.2.4.5. Strategic Initiatives
6.2.4.6. SWOT Analysis
6.2.5. Intertek Group plc
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Geographic Foothold
6.2.5.4. Product Benchmarking
6.2.5.5. Strategic Initiatives
6.2.5.6. SWOT Analysis
6.2.6. Pharmaceutical Product Development, LLC.
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Geographic Foothold
6.2.6.4. Product Benchmarking
6.2.6.5. Strategic Initiatives
6.2.6.6. SWOT Analysis
6.2.7. Exova Group plc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Geographic Foothold
6.2.7.4. Product Benchmarking
6.2.7.5. Strategic Initiatives
6.2.7.6. SWOT Analysis
6.2.8. Boston Analytical
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Geographic Foothold
6.2.8.4. Product Benchmarking
6.2.8.5. Strategic Initiatives
6.2.8.6. SWOT Analysis
6.2.9. Charles River Laboratories International, Inc
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Geographic Foothold
6.2.9.4. Product Benchmarking
6.2.9.5. Strategic Initiatives
6.2.9.6. SWOT Analysis
6.2.10. West Pharmaceutical Services
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Geographic Foothold
6.2.10.4. Product Benchmarking
6.2.10.5. Strategic Initiatives
6.2.10.6. SWOT Analysis
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Pharmaceutical Analytical Testing Outsourcing Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Penetration & Growth Prospect Mapping
3.4. SWOT Analysis, By Factor
3.4.1. Political
3.4.2. Economic
3.4.3. Technological
3.5. Industry Analysis - Porter’s
Chapter 4. Pharmaceutical Analytical Testing Outsourcing: Services Estimates & Trend Analysis
4.1. Pharmaceutical Analytical Testing Services Outsourcing Market Share, 2015 & 2025
4.2. Market Size, Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following services:
4.2.1. Bioanalytical Testing
4.2.1.1. Clinical
4.2.1.2. Non Clinical
4.2.2. Method Development & Validation
4.2.2.1. Extractable & Leachable
4.2.2.2. Impurity Method
4.2.2.3. Technical Consulting
4.2.2.4. Others
4.2.3. Stability Testing
4.2.3.1. Drug Substance
4.2.3.2. Stability indicating Method Validation
4.2.3.3. Accelerated Stability Testing
4.2.3.4. Photostability Testing
4.2.3.5. Others
4.2.4. Others
Chapter 5. Pharmaceutical Analytical Testing Outsourcing: Regional Estimates & Trend Analysis
5.1. Pharmaceutical Analytical Testing Services Outsourcing Movement Analysis & Market Share, 2015 & 2025
5.2. North America
5.2.1. U.S.
5.2.1.1. U.S. revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.2.2. Canada
5.2.2.1. Canada revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.3. Europe
5.3.1. UK
5.3.1.1. UK revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.3.2. Germany
5.3.2.1. Germany revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Japan
5.4.1.1. Japan revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.4.2. China
5.4.2.1. China revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.5. Latin America
5.5.1. Brazil
5.5.1.1. Brazil revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.5.2. Mexico
5.5.2.1. Mexico revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
5.6. MEA
5.6.1. South Africa
5.6.1.1. South Africa revenue estimates and forecasts by, services 2014 - 2025 (USD Million)
Chapter 6. Competitive Landscape
6.1. Strategy Framework
6.2. Company Profiles
6.2.1. SGS SA
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Geographic Foothold
6.2.1.4. Product Benchmarking
6.2.1.5. Strategic Initiatives
6.2.1.6. SWOT Analysis
6.2.2. Toxikon, Inc
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Geographic Foothold
6.2.2.4. Product Benchmarking
6.2.2.5. Strategic Initiatives
6.2.2.6. SWOT Analysis
6.2.3. Eurofins Scientific
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Geographic Foothold
6.2.3.4. Product Benchmarking
6.2.3.5. Strategic Initiatives
6.2.3.6. SWOT Analysis
6.2.4. Pace Analytical Services LLC.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Geographic Foothold
6.2.4.4. Product Benchmarking
6.2.4.5. Strategic Initiatives
6.2.4.6. SWOT Analysis
6.2.5. Intertek Group plc
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Geographic Foothold
6.2.5.4. Product Benchmarking
6.2.5.5. Strategic Initiatives
6.2.5.6. SWOT Analysis
6.2.6. Pharmaceutical Product Development, LLC.
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Geographic Foothold
6.2.6.4. Product Benchmarking
6.2.6.5. Strategic Initiatives
6.2.6.6. SWOT Analysis
6.2.7. Exova Group plc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Geographic Foothold
6.2.7.4. Product Benchmarking
6.2.7.5. Strategic Initiatives
6.2.7.6. SWOT Analysis
6.2.8. Boston Analytical
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Geographic Foothold
6.2.8.4. Product Benchmarking
6.2.8.5. Strategic Initiatives
6.2.8.6. SWOT Analysis
6.2.9. Charles River Laboratories International, Inc
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Geographic Foothold
6.2.9.4. Product Benchmarking
6.2.9.5. Strategic Initiatives
6.2.9.6. SWOT Analysis
6.2.10. West Pharmaceutical Services
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Geographic Foothold
6.2.10.4. Product Benchmarking
6.2.10.5. Strategic Initiatives
6.2.10.6. SWOT Analysis
